In the Claims:

Please cancel claims 31, 32, 33, and 37.

Please amend the claims as follows:

14. (Amended) A compound according to claim 6 wherein X is O.

20. (Amended) A compound according to claim 4 wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, -CN, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino, heterocycleC_{1-8}alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and $C(O)OR^{11}$, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, $-NO_2$, $-NH_2$, C_{1-8}alkylamino, CF_3, or alkoxy;

a3 R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

a4 26. (Amended) A compound according to claim 4 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

27. (Amended) A method of treatment of a viral infection in a mammal comprising administering to said mammal an antivirally effective amount of a compound according to claim 2.

a5 29. (Amended) A method of inhibiting HIV reverse transcrptase comprising administering to a mammal an effective amount of a compound according to claim 2.

30. (Amended) A method of preventing HIV infection, or of treating HIV infection, comprising administering to a mammal an effective amount of a compound according to claim 2.

a6 34. (Amended) A pharmaceutical composition comprising an effective amount of a compound according to claim 2 together with a pharmaceutically acceptable carrier.

Please add the following new claims:

38. A compound according to claim 6 wherein

a7 R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, $-CN$, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally

substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino, heterocycleC_{1-8}alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and $C(O)OR^{11}$, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, $-NO_2$, $-NH_2$, C_{1-8}alkylamino, CF_3, or alkoxy;

R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

39. A compound according to claim 7 wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, -CN, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino, heterocycleC_{1-8}alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and $C(O)OR^{11}$, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, $-NO_2$, $-NH_2$, C_{1-8}alkylamino, CF_3, or alkoxy;

R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

40. A compound according to claim 17 wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, -CN, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino, heterocycleC_{1-8}alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and $C(O)OR^{11}$, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, $-NO_2$, $-NH_2$, C_{1-8}alkylamino, CF_3, or alkoxy;

R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

41. A compound according to claim 18 wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, -CN, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the

para position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino, heterocycleC_{1-8}alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and $C(O)OR^{11}$, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, $-NO_2$, $-NH_2$, C_{1-8}alkylamino, CF_3, or alkoxy;

R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

42. A compound according to claim 19 wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8}alkyl, C_{1-8}alkylamino, alkoxy, C_{3-6}cycloalkylC_{2-6}alkenyl, C_{6-14}arylC_{2-6}alkenyl, -CN, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6}alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6}alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6}cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8}alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, -CN, $-NO_2$, C_{1-8}alkylamino,

heterocycleC_{1-8}alkyl, -C(O)NH_2, -S(O)R^7, -$S(O)_2R^7$, -C(O)R^7, -$NS(O)_2R^7$, -$S(O)_2NR^8R^9$, -$S(O)_2NHR^{11}$, -SO_2R^{11}, -OR^{11} , -C(O)R^{11}, -C(O)NR^{11}, -C(O)OR^{11}, -NR^{11}, -$NC(O)R^{11}$, heterocycleC_{2-6}alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8}alkyl, and C(O)OR^{11}, and C_{1-8}alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with -C(O)R^{11};

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8}alkyl, -NO_2, -NH_2, C_{1-8}alkylamino, CF_3, or alkoxy;

R^{11} is C_{1-8}alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8}alkyl, -$S(O)_2NR^8R^9$, -NR^8R^9, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8}alkyl; or a pharmaceutically acceptable derivative thereof.

43. A compound according to claim 6 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

44. A compound according to claim 7 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

45. A compound according to claim 17 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

46. A compound according to claim 18 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

47. A compound according to claim 19 wherein R^1 is C_{6-14} aryl substituted in the meta position, particularly with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14}aryl substituted with C_{1-8}alkyl, in particular methyl.

48. A method of treatment of a viral infection in a mammal comprising administering to said mammal an antivirally effective amount of a compound according to claim 4.

49. A method of treatment of a viral infection in a mammal comprising administering to said mammal an antivirally effective amount of a compound according to claim 23.

a7

50. A method of inhibiting HIV reverse transcrptase comprising administering to a mammal an effective amount of a compound according to claim 4.

51. A method of inhibiting HIV reverse transcrptase comprising administering to a mammal an effective amount of a compound according to claim 23.

52. A method of preventing HIV infection, or of treating HIV infection, comprising administering to a mammal an effective amount of a compound according to claim 4.

53. A method of preventing HIV infection, or of treating HIV infection, comprising administering to a mammal an effective amount of a compound according to claim 23.

54. A pharmaceutical composition comprising an effective amount of a compound according to claim 4 together with a pharmaceutically acceptable carrier.

55. A pharmaceutical composition comprising an effective amount of a compound according to claim 23 together with a pharmaceutically acceptable carrier.